Oxford BioDynamics has confirmed that Stephen Diggle has stepped down as a director of the AIM-listed precision diagnostics company.

Diggle, who has served as a non-executive director for nine years, had previously indicated his intention to leave the board ahead of the company’s AGM.

The company added that Vulpes Investment Management, which is controlled by Diggle, remains its largest shareholder through the Vulpes Testudo Fund and Vulpes Life Sciences Fund.